Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn

09 Jul 2012

• By Jessica Merrill and Wendy Diller

Related Content

Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation

08 Nov 2011

GSK Airs Phase III Data For Weekly GLP-1 Albiglutide, Plans To File By Year-End

03 Apr 2012

AstraZeneca/BMS's Dapagliflozin Needs European Epidemiological Study, But Headed For Strong Label

23 Apr 2012

Weeks After <em>Bydureon</em> Launch, Amylin Looks Like A Takeout Target

29 Mar 2012

$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership

30 Jun 2012

Diabetes Leaders Lilly, Sanofi Give A Glimpse Of GLP-1 Strategy

14 Jun 2012

Amylin’s<em> Bydureon</em> Approval: How Does It Sit With Novo Nordisk?

06 Feb 2012

Failed Head-To-Head Study Clouds Bydureon's Commercial Future

03 Mar 2011

Related Companies

Bristol Myers Squibb Company

Bristol Myers Squibb Company

AstraZeneca PLC

Novo Nordisk A/S

Eli Lilly and Company

Merck & Co., Inc.

Boehringer Ingelheim GmbH

Sanofi

GSK plc

Zealand Pharma A/S

Novo Nordisk A/S

Boehringer Ingelheim GmbH

GSK plc

Intarcia Therapeutics, Inc.

Zealand Pharma A/S

Additional Topics

Deals BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.